BPC-157+TB-500 (WOLVERINE STACK) 10MG

The “Wolverine Stack” (BPC‑157 + TB‑500) pairs two investigational peptides commonly used together in regenerative and recovery protocols. Below is a concise summary of reported benefits, typical uses, administration approaches, and safety considerations. This is informational only — use under qualified medical supervision.

What each peptide does (mechanism highlights)

• BPC‑157: gastric‑derived 15‑aa peptide that promotes angiogenesis, collagen synthesis, mucosal protection, anti‑inflammatory signaling, and accelerated healing of muscle, tendon, ligament, gut lining, and skin.
• TB‑500 (Thymosin β4 fragment): promotes cell migration (actin modulation), angiogenesis, reduced fibrosis, and tissue remodeling—helps mobilize repair cells to injury sites.

Why they’re stacked (synergy)

• Complementary actions: BPC‑157 supports local tissue repair and gut/soft‑tissue healing; TB‑500 enhances cell migration, angiogenesis and remodels the extracellular matrix. Together they may accelerate repair, reduce scarring, improve functional recovery, and better address both local tissue repair (BPC‑157) and systemic microvascular/cellular repair (TB‑500).

Reported/putative benefits

• Faster healing of tendon, ligament, muscle and surgical injuries
• Reduced inflammation, swelling, and pain in injured areas
• Improved tendon and ligament strength and flexibility; reduced fibrosis/scar tissue
• Enhanced recovery after orthopedic surgery or sports injury
• Improved gut mucosal healing (BPC‑157 specific) for ulcers, leaky gut, IBD models
• Potentially faster return-to-function and improved rehabilitation outcomes

Typical uses / indications (research/clinical contexts)

• Acute soft‑tissue injuries (strains, partial tears) and post‑op healing
• Chronic tendinopathies, plantar fasciitis, rotator cuff, Achilles tendon injuries
• Muscle tears and overuse injuries
• Chronic joint pain with soft‑tissue component; adjunct to PT/rehab
• GI mucosal injuries or inflammatory gut conditions (primarily BPC‑157)

Administration & common dosing patterns (examples used in practice; not prescriptive)

• Routes: subcutaneous (most common), intramuscular (near injury), oral/sublingual for gut indications (BPC‑157). Do not self‑treat without training.
• Example TB‑500 dosing: 2–5 mg total per week (e.g., 2 mg twice weekly) for 2–6 weeks, sometimes followed by maintenance dosing.
• Example BPC‑157 dosing: 250–500 mcg once or twice daily (site‑directed injections often used near injury) for 2–6 weeks.
• Combined-cycle approach: induction/intensive phase (both peptides for 2–6 weeks) then reassess; maintenance or repeat cycles as clinically indicated.
• A 10 mg vial of each peptide (or combined supply) is commonly reconstituted to yield multiple doses. Protocols vary widely between clinicians.